This may be due to the extremely short survival time of GBM patients, which makes prognostic stratification more challenging; (2) we show that REST exerts its oncogenic function through different mechanisms that include enhancing GBM cell proliferation and survival, as well as reducing the expression of neural differentiation genes (but largely/mostly not via HAR1A repression). The gene discussed is REST; the disease is glioblastoma.